The Alport Syndrome Gene Panel by NGS is a comprehensive molecular test designed to detect genetic mutations associated with Alport Syndrome, a hereditary disorder affecting the kidneys, hearing, and eyes. Metropolis Healthcare uses advanced next-generation sequencing to analyze key collagen-related genes responsible for this condition. This test helps confirm diagnosis, guide treatment decisions, and support genetic counseling for families. It is especially useful when clinical signs suggest inherited kidney disease or early-onset hearing loss.
Price:
Rs. 21,000.00
Sample Type: EDTA BLOOD
Fasting Not Required
Notes:G0165
Frequently Asked Questions (FAQ's):
What does this test include at Metropolis Healthcare?
It includes targeted NGS-based analysis of genes known to cause Alport Syndrome, primarily COL4A3, COL4A4, and COL4A5.
How does Metropolis Healthcare perform this test?
DNA is isolated from an EDTA blood sample and sequenced using high-precision next-generation sequencing platforms.
Who should take this test at Metropolis Healthcare?
Individuals with suspected hereditary kidney disease, early hearing loss, hematuria, or a family history suggestive of Alport Syndrome.
What sample is required at Metropolis Healthcare?
A standard EDTA blood sample is required for DNA extraction and sequencing.
How does this panel help in diagnosis at Metropolis Healthcare?
It confirms the genetic cause, determines inheritance patterns, and guides evaluation of at-risk family members.
Is any preparation needed before giving the sample at Metropolis Healthcare?
No fasting or special preparation is needed; routine blood draw is sufficient.
How long does the test take at Metropolis Healthcare?
Turnaround time typically ranges from several days to a few weeks, depending on analysis depth.
When will I receive the report from Metropolis Healthcare?
Reports are released as per the molecular diagnostics schedule, along with expert genetic interpretation.